Literature DB >> 17579227

Limited family structure and BRCA gene mutation status in single cases of breast cancer.

Jeffrey N Weitzel1, Veronica I Lagos, Carey A Cullinane, Patricia J Gambol, Julie O Culver, Kathleen R Blazer, Melanie R Palomares, Katrina J Lowstuter, Deborah J MacDonald.   

Abstract

CONTEXT: An autosomal dominant pattern of hereditary breast cancer may be masked by small family size or transmission through males given sex-limited expression.
OBJECTIVE: To determine if BRCA gene mutations are more prevalent among single cases of early onset breast cancer in families with limited vs adequate family structure than would be predicted by currently available probability models. DESIGN, SETTING, AND PARTICIPANTS: A total of 1543 women seen at US high-risk clinics for genetic cancer risk assessment and BRCA gene testing were enrolled in a prospective registry study between April 1997 and February 2007. Three hundred six of these women had breast cancer before age 50 years and no first- or second-degree relatives with breast or ovarian cancers. MAIN OUTCOME MEASURE: The main outcome measure was whether family structure, assessed from multigenerational pedigrees, predicts BRCA gene mutation status. Limited family structure was defined as fewer than 2 first- or second-degree female relatives surviving beyond age 45 years in either lineage. Family structure effect and mutation probability by the Couch, Myriad, and BRCAPRO models were assessed with stepwise multiple logistic regression. Model sensitivity and specificity were determined and receiver operating characteristic curves were generated.
RESULTS: Family structure was limited in 153 cases (50%). BRCA gene mutations were detected in 13.7% of participants with limited vs 5.2% with adequate family structure. Family structure was a significant predictor of mutation status (odds ratio, 2.8; 95% confidence interval, 1.19-6.73; P = .02). Although none of the models performed well, receiver operating characteristic analysis indicated that modification of BRCAPRO output by a corrective probability index accounting for family structure was the most accurate BRCA gene mutation status predictor (area under the curve, 0.72; 95% confidence interval, 0.63-0.81; P<.001) for single cases of breast cancer.
CONCLUSIONS: Family structure can affect the accuracy of mutation probability models. Genetic testing guidelines may need to be more inclusive for single cases of breast cancer when the family structure is limited and probability models need to be recreated using limited family history as an actual variable.

Entities:  

Mesh:

Year:  2007        PMID: 17579227     DOI: 10.1001/jama.297.23.2587

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  53 in total

Review 1.  The role of BRCA mutation testing in determining breast cancer therapy.

Authors:  Alison H Trainer; Craig R Lewis; Kathy Tucker; Bettina Meiser; Michael Friedlander; Robyn L Ward
Journal:  Nat Rev Clin Oncol       Date:  2010-11-09       Impact factor: 66.675

2.  Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.

Authors:  Dezheng Huo; Ruby T Senie; Mary Daly; Saundra S Buys; Shelly Cummings; Jacqueline Ogutha; Kisha Hope; Olufunmilayo I Olopade
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

3.  Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.

Authors:  Mary S Beattie; Beth Crawford; Feng Lin; Eric Vittinghoff; John Ziegler
Journal:  Genet Test Mol Biomarkers       Date:  2009-02

4.  Electronically ascertained extended pedigrees in breast cancer genetic counseling.

Authors:  V Stefansdottir; H Skirton; O Th Johannsson; H Olafsdottir; G H Olafsdottir; L Tryggvadottir; J J Jonsson
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

5.  Cancer Genetic Counselors' Current Practices and Attitudes Related to the Use of Tumor Profiling.

Authors:  LeAnne Noelle Goedde; Nathan W Stupiansky; Melissa Lah; Kimberly A Quaid; Stephanie Cohen
Journal:  J Genet Couns       Date:  2017-01-13       Impact factor: 2.537

6.  Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

Authors:  Brian S Finkelman; Wendy S Rubinstein; Sue Friedman; Tara M Friebel; Shera Dubitsky; Niecee Singer Schonberger; Rochelle Shoretz; Christian F Singer; Joanne L Blum; Nadine Tung; Olufunmilayo I Olopade; Jeffrey N Weitzel; Henry T Lynch; Carrie Snyder; Judy E Garber; Joellen Schildkraut; Mary B Daly; Claudine Isaacs; Gabrielle Pichert; Susan L Neuhausen; Fergus J Couch; Laura van't Veer; Rosalind Eeles; Elizabeth Bancroft; D Gareth Evans; Patricia A Ganz; Gail E Tomlinson; Steven A Narod; Ellen Matloff; Susan Domchek; Timothy R Rebbeck
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

Review 7.  The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers.

Authors:  Ana Cristina Vargas; Leonard Da Silva; Sunil R Lakhani
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

8.  Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment.

Authors:  Michael J Hall; James J Dignam; Olufunmilayo I Olopade
Journal:  J Genet Couns       Date:  2008-06-25       Impact factor: 2.537

9.  Evaluation of a heredofamilial cancer unit in increasing family history collection and genetic counseling referrals among Spanish oncologists at a university hospital.

Authors:  Iván Márquez-Rodas; Sara López-Tarruella; Yolanda Jerez; Mercedes Cavanagh; Sara Custodio; Daniel López-Trabada; Beatriz Moya; Sara Pérez; Ana B Rupérez; Miguel Martín
Journal:  J Genet Couns       Date:  2013-06-16       Impact factor: 2.537

10.  Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care.

Authors:  Patricia Ashton-Prolla; Juliana Giacomazzi; Aishameriane V Schmidt; Fernanda L Roth; Edenir I Palmero; Luciane Kalakun; Ernestina S Aguiar; Susana M Moreira; Erica Batassini; Vanessa Belo-Reyes; Lavinia Schuler-Faccini; Roberto Giugliani; Maira Caleffi; Suzi Alves Camey
Journal:  BMC Cancer       Date:  2009-08-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.